Shares of Metsera Inc. (MTSR) have gained 6.8% over the past four weeks to close the last trading session at $35.32, but ...

Metsera is not currently offering a proper buying opportunity. See if the stock goes on to build a sound pattern that could ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin ...

Metsera is advancing promising obesity treatments with amylin and GLP-1 analogs, eyeing competitive efficacy and buyout potential. Read why MTSR stock is a hold.

Wells Fargo emphasized that Metsera’s long half-life drugs may provide improved tolerability by enabling gradual buildup of drug exposure and avoiding fluctuations that increase adverse events.

Investing.com - Wells Fargo initiated coverage on Metsera Inc (NASDAQ:MTSR), a $2.91 billion biotech company trading at $27.71, with an overweight rating and a $65.00 price target on Friday. The ...

Get the latest Metsera, Inc. (MTSR) stock news and headlines to help you in your trading and investing decisions.

Wells Fargo emphasized that Metsera’s long half-life drugs may provide improved tolerability by enabling gradual buildup of drug exposure and avoiding fluctuations that increase adverse events. The ...

Cantor Fitzgerald reiterated an Overweight rating on Metsera Inc (NASDAQ:MTSR) following promising results from the company’s MET-233i obesity treatment. The research firm maintained its bullish ...

Metsera is also developing a combination therapy that includes MET-233i and a monthly administered GLP-1 class obesity drug candidate MET-097i.

About Metsera Metsera is a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and metabolic diseases.

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, ...